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ABSTRACT 
Objectives: Estimate physical and mental health effects of the Eyjafjallajökull volcanic 
eruption on nearby residents. 
Design: Cross sectional study. 
Setting: The Icelandic volcano Eyjafjallajökull erupted 14 April 2010. The eruption 
lasted for about six weeks and was explosive, ejecting some 8 million tons of fine 
particles into the atmosphere. Due to prevailing winds, the ash spread mostly to the south 
and south-east, first over the rural region to the south, later over the Atlantic Ocean and 
Europe, closing European air space for several days.  
Participants: Residents (n=207) of the most ash-exposed rural area south and east of 
the volcano.  
Methods: The study period was 31 May to 11 June 2010. Participants were examined by 
a physician. To ascertain respiratory health, standardised spirometry was performed 
before and after the use of a bronchodilator. All adult participants answered 
questionnaires about mental and physical health, their children’s health and the use of 
protective equipment.  
Results: Every other adult participant reported irritation in eyes and upper airway when 
exposed to volcanic ash. Adults (n=26) and children (n=5) with pre-existing asthma 
frequently reported worsening of their symptoms. No serious health problems were found 
requiring hospitalisation could be attributed to the eruption. The majority of the residents 
reported no abnormal physical or mental symptoms to the examining physician. 
Compared to an age- and gender- matched control group, the ash-exposed inhabitants 
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reported lower smoking rates and were less likely to have ventilation impairment. Less 
than 10% of the participants reported symptoms of stress, anxiety or depression.  
 
Conclusions: Short-term ash exposure was associated with upper airway irritation 
symptoms and exacerbation of pre-existing asthma but did not contribute to serious 
health problems. The exposure did not impair respiratory function compared to controls. 
Outdoor use of protective glasses and face masks protected against irritation in eyes and 
upper airway.  
 
ARTICLE SUMMARY 
Article focus 
• Exposure to volcanic ash and gases can have adverse effects on respiratory health. 
• Natural hazards, such as volcanic eruptions, can be stressful events. 
• Value of preventive measures for those exposed to a volcanic eruption.  
Key messages 
• The short term effects of ash exposure were associated with irritation in eyes and 
upper airway and exacerbation of pre-existing asthma, but did not contribute to 
serious health problems or impair respiratory function as compared to controls. . 
• Individuals with pre-existing respiratory and mental conditions need special 
attention and are more prone to developing symptoms following exposure to 
volcanic eruptions and volcanic ash.  
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• The use protective glasses and face masks prevented or relieved irritation 
symptoms from the eyes and upper airway. 
Strengths and limitations of this study 
• The whole population living within a confined area close to the volcano was 
contacted and the response rate was high (93%) which minimised the risk of 
selection bias, though some sensitive individuals had probably left the area, and 
some elderly individuals did not participate in the survey.  
• Standardised methods were used in measuring respiratory function and 
questionnaires were also standardised, allowing for comparisons with other 
studies. 
• Results from the spirometry were compared to results from an age-and gender 
matched Icelandic control group from a previous study which had been performed 
using identical methods. 
• The population was small (N=207) and due to stressful circumstances during the 
test period, not all participants completed the questionnaire, which limited the 
statistical power of our analyses. 
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INTRODUCTION 
On 14 April 2010 an explosive summit crater eruption began in Eyjafjallajökull 
(Eyjafjalla Glacier), a volcano that is situated in south Iceland (figure 1). In the early 
phases of the eruption, fine-grained ash was ejected up to 10 km into the atmosphere, 
disturbing air traffic in Europe for days. In Iceland, the rural regions south and south-east 
of the volcano were heavily exposed to falling ash. The volcano ejected some 250 million 
tons of ash, of which 8 million tons were particles 2.8 - 28 µm in diameter.1 2 3 4 Particles 
with a diameter of less than 10 µm are inhalable and can compromise respiratory health. 
Despite the falling ash that changed day to night, many inhabitants, mostly farmers, 
remained in the area to work on their farms and tend their livestock.  
   Apart from the immediate, life-threatening hazards following a volcano eruption, such 
as pyroclastic flows, mudslides and glacial outburst floods, several other health risks are 
associated with living close to an active volcano.5 Short term exposure to volcanic gases  
can trigger asthma attacks, and has been associated with respiratory morbidity and 
mortality and increased irritation of the respiratory tract.6 Exposure for longer time 
periods to volcanic ash and gases have been associated with increases in cardiovascular 
symptoms7 and increased rates of chronic bronchitis and other respiratory symptoms,8 9 
also in children.10 11 Symptoms of skin and eyes have also been reported.12 The chemical 
and physical properties of volcanic ash vary a great deal between eruptions and 
volcanoes, making it difficult to generalise about the toxicity of ash from individual 
eruptions.12 
   Volcanic eruptions are violent natural disasters that impose a threat to health as well as 
to livestock and property. During eruptions the population may have to be evacuated, 
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depending on risk assessment, and uncertainty and stress experienced during the eruption 
can influence mental well-being.13 14 The aim of this study was to examine medically the 
most exposed population and evaluate possible acute physical and mental health effects 
associated with the Eyjafjallajökull eruption. In addition the effectiveness of protective 
measures taken was evaluated. 
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METHODS 
The study area of the volcanic eruption 
The volcanic eruption of the Eyjafjallajökull volcanic system began on 20 March 2010 
with a small flank eruption which produced negligible ash. After a day of no volcanic 
activity, an eruption started within the Eyjafjallajökull caldera on 14 April.15 This phase 
was explosive, sending fine-grained, phreato-magmatic ash into the atmosphere. The 
eruption lasted some 6 weeks, until the end of  May 2010. During that time the wind 
direction was predominantly west and north-west, therefore most of the ash fall was to 
the south and south-east of the volcano (figure 1). This area is mostly rural farmland. For 
this study, inhabitants of the area between the river Markarfljót and the village of Vík 
were investigated, as they were most exposed. Most of the inhabitants are farmers and 
many also have income from tourism. 
 
The volcanic ash 
The ash was trachy-andesitic, 58% silica by mass, but contained very little quartz and no 
cristobalite was detected.1 2 3 4 In ash samples collected during the first 3 days of the 
eruption, upwards of 25% of particles by mass were less than 10 µm in diameter (PM10) 
and therefore inhalable. The fraction of fine particles was lower for ash ejected later in 
the eruption,1 but still the amount of ash produced was considerable, and the fine- grained 
ash was also easily re-suspended. The concentration of PM10 in Vík, on the eastern border 
of the study area, showed that the concentration exceeded the recommended health limit 
of 50 µg per cubic meter 80% of the days of May 2010.4 
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A network of diffusion tubes in the ground area showed no evidence of fumigation by 
sulphur dioxide, the predominant volcanic gas in the ash plume, in the last 3 weeks of the 
eruption.16 
 
Target population and recruitment 
During the eruption some 223 individuals lived in the study area and were exposed to ash 
fall. All the inhabitants were invited to a medical examination during the time period 31 
May to 11 June 2010. An announcement was put up in local official buildings and 
information given on radio and TV news. Also, inhabitants were contacted by telephone 
by staff from the two local primary healthcare centres in the area. The majority of 
inhabitants were examined at temporary medical offices at a community centre or at a 
primary health care centre, a few were examined in their homes. 
 
Medical examination  
A physician interviewed and examined all subjects. Former and present mental and 
physical health was explored. Subjects were asked if they experienced any change in 
health or new symptoms that they related to the ash and the volcanic eruption. The 
medical history of young children was obtained from their parents. In case of abnormal 
findings the subjects were referred to their Primary Health Care Centre for further 
examination and treatment.  
 
Spirometry 
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The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) 
values were obtained by spirometry in all subjects five years or older, according to ATS 
criteria in the same way and by the same field workers as had conducted the Burden of 
Obstructive Lung Disease (BOLD) multicentre study in Iceland.17 18 The spirometry was 
conducted by trained and certified personnel and the medical examination was conducted 
by doctors, all from the Landspitali University Hospital.  
Briefly, testing was conducted with the participant in a sitting position wearing a nose 
clip and a disposable mouthpiece using the NDD Easy One™ spirometer (NDD 
Medizintechnik, Zurich, Switzerland). Pre- and post-bronchodilator tests were carried 
out, with separate measurements performed before and ≥15 minutes after two puffs of 
salbutamol (200 µg). The primary reference equations used are derived from the third 
United States National Health and Nutrition Examination Survey (NHANES III) for adult 
Caucasian men and women.19 
   The criteria for chronic obstructive pulmonary disease (COPD) are defined by the 
Global Initiative of Chronic Obstructive Lung Disease.18 COPD Gold stage 1 was defined 
as FEV1/FVC ratio < 0.7 after bronchodilation and GOLD stage II as FEV1/FVC ratio < 
0.7 and FEV1 ≤ 80% predicted after bronchodilation. Reversibility of airway obstruction 
was calculated as a change in FEV1 and expressed as a change in percentage (∆%). 
   For analysis of the spirometry results in those over 40 years of age, a subset of the 
BOLD cohort18 was used as a control group, with three age- and gender- matched 
controls from the BOLD (random general) population for each participant exposed to 
volcanic ash.  
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Questionnaires 
Participants over the age of 18 were asked to fill out questionnaires with questions about 
physical health, mental health, exposure to volcanic ash, experience of earthquakes, 
rumbling and smell from the volcano, and use of protective face masks and glasses. If 
necessary, the questionnaires were read to them by researchers. 
   Respiratory health before the eruption was assessed by the European Community 
Respiratory Health Survey (ECRHS) II questionnaire.20 From the main ECRSH 
Questionnaire, we used questions about wheeze, cough and phlegm prevalence, history of 
respiratory and heart disease (questions number 1-3, 6-10 and 14, and question 7 from the 
screening questionnaire).  
   The participants were also asked if they had experienced other respiratory or eye 
symptoms, muscular pain, fatigue, nausea, headache, stomach pain or insomnia before 
and/or after the eruption started. If the symptoms had started after the eruption they were 
asked to quantify how much these symptoms affected their daily life, on a three point 
scale (rather little, rather much, and very much).  
   Parents answered seven questions about respiratory symptoms, headache, stomach 
ache, insomnia, anxiety, depression and behavioural changes in children under 18 years 
of age. If these symptoms had started after the eruption they were asked to quantify them 
on a three-level scale.  
   There were also questions about medical emergencies and use of medication, injuries 
and accidents related to the eruption.  
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   Mental health was assessed with three different psychometric scales which all had 
previously been translated into Icelandic and used in other studies. When measuring 
psychological morbidity in relationship with the eruption, we used the General Health 
Questionnaire (GHQ-12),21 22 the Depression, Anxiety and Stress Scale (DASS)23 and the 
Post-Traumatic Stress Disorder (PTSD) Symptom Scale, Self-Report version (PSS-SR).24 
25
 Each questionnaire was evaluated, and, if inadequately answered, excluded. 
   For GHQ-12, a score of more than 2 was considered indicative of experiencing more 
mental distress than usual (Bimodal score).22 
   For PSS-SR, a score of more than 14 considered indicative of PTSD-symptoms in the 
subjects.25 
   For DASS, a score was given for each of the three dimensions addressed in the 
questionnaire. A score of more than 10 for depression, 8 for anxiety, and 15 for stress 
indicate symptom severity, from mild to extreme, as defined by Lovibond and 
Lovibond.23 DASS and PSS-SR questionnaires were not administered on the first day of 
the study, but participants were given the option of filling out the questionnaires and 
mailing them.  
   Participants were asked how they had experienced ash fall, heard or been awakened by 
noise from the volcano, felt earthquakes, smell, or limited vision outside due to ash fall at 
their homes, how many days they to stay inside because of ash fall, how many hours they 
usually worked outdoors and if they had used protective equipment. Finally, participants 
were asked if they had received help or services from a number of organisations and 
institutions, and if they were satisfied with it. 
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   Smoking history was investigated by asking subjects whether they were current 
smokers, ex-smokers or never-smokers. Based on this information the subjects were 
classified into Never-smoker, Ex-smoker, and Smoker. 
 
Statistical analysis 
All data were entered into a database by one observer. The analysis was mainly 
descriptive. We used SPSS software version 18 and R (R Core Development team) 
version 2.13.0. In comparisons between groups, we used student's t-test and χ2 test. 
Individuals with incomplete data were not excluded from the study, but non-replies to any 
single questions were excluded from individual analyses. 
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RESULTS 
Altogether 207 individuals of 223 individuals (93%) who lived in the study area at the 
time of the eruption participated in the study. Local health workers, who recruited the 
participants, reported that inhabitants of two of about 80 farms had refused to participate, 
and 14 individuals who had initially signed up did not participate. 
   The most common reason for non-participation reported to the recruiters was either  
“being busy”, “not having any health problems” , or “old age” (reported by relatives). Of 
the 207 participating residents, 40 were under 18 years of age. Most of them, 202 (98%) 
were medically examined, 164 adults and 38 children. The same proportion was tested 
with spirometry, and 156 adults were tested both before and after bronchodilation. All 
adults received questionnaires about symptoms and general health (GHQ-12). PSS-SR 
and DASS were administered to 150 people. Main demographic characteristics, symtom- 
and smoking rates reported in adults are shown in table 1. The survey included 40 
children under 18 years of age of which 21 (53%) were girls.  
    The age distribution of the whole population is given in figure 2. 
 
Physical examination 
The physician’s judgement was that 126 (62%) of the participants were healthy. In the 
physician interview, 26 (13%) of adults reported history of asthma or other chronic 
respiratory diseases, 32 (16%) reported symptoms and signs other than respiratory, and 
27 (13%) individuals indicated a history of mental symptoms. Asthma rates reported to 
physicians were similar to that reported in questionnaires. Of those with a history of 
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asthma or other respiratory diseases, 38% had a normal spirometric test but 39% reported 
worsening of the disease when exposed to ash. Rates of chronic cough and phlegm were 
also similar (8-10%). Smoking was more common among controls than the volcano-
exposed population (p<0.01) (table 1). Some reported to physicians that upper respiratory 
symptoms subsided when avoiding exposure by staying inside or wearing dust masks and 
also that falling “fresh” ash was more bothersome than “older” ash re-suspended by wind. 
Farming was reported as the main occupation (63%) of adult participants.  
 
Spirometry  
Among the  202 residents who underwent spirometry 37 (18%) were found to have 
impaired respiratory function by the examining physician.  
Participants aged 40 years or older had on average a higher FEV1 than the controls 
(p=0.003) and they also showed less airflow reversibility (p<0.0001). After 
bronchodilation, 20% of those 40 years of age or older fulfilled the criteria for COPD 
stage I or higher, which was identical to that found among the controls from the general 
population (table 2).18 
 
Questionnaires 
Almost half of the adult participants (43%) experienced symptoms from the upper 
airways and eyes during the ash fall. Almost everybody or 153 of 161 (96%) found facial 
mask and glasses protective against respiratory and eye symptoms when staying outdoor 
during ash fall. All residents participating in the study were exposed to ash fall at their 
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homes and almost all (88 %) had to stay inside at least one day and one third (34%) for 6 
days or more. The most common self-reported symptoms reported by adult participants 
are shown in table 1. Men and women had similar rates of symptoms, except that women 
tended to report more throat and upper airway irritation (p=0.06, Student’s t-test). 
   Females reported more frequently mental health deterioration than men, according to 
the General Health Questionnaire (GHQ) and Depression, Anxiety, Stress Scale (DASS) 
and the highest rates were found in those between 35-49 years of age (table 3). Symptoms 
of post-traumatic stress syndrome (PSS-SR) were found in 7% of participants, and were 
more common among femal s than males and in those slightly older (50-64 years old). 
Very little effect on mental health was reported in the age-group 18-34 years of age. 
   Table 4 shows the proportions of individuals experiencing mental distress by level of 
exposure (experience of the volcanic eruption). Experiencing a feeling of helplessness or 
fear for the lives of others or oneself during the eruption period was associated with 
higher rates of PTSD symptoms. The frequency of mental distress (as measured by GHQ) 
was significantly (p<0.05) higher in those who had been awakened by noise. 
   Symptoms of depression and anxiety (DASS) were more common among those who 
had experienced earthquakes and had thought that their lives were in danger (table 4). 
   Many children of school age were not in the area during the heaviest ash fall; still, 13 
(28%) of parents reported in the questionnaires that their child had experienced throat or 
upper airway irritation symptoms (data not shown). Eight (13%) reported headaches, 
while three parents (7%) reported that their child or children had had nausea or stomach 
pain during the eruption. Of the 40 participating children, 5 had a previous history of 
asthma and they all reported that they had had more symptoms during the ash fall and 
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needed more anti-asthmatic medication than usual in the medical interview. Regarding 
mental distress, 39% of adults with children reported increased worries or anxiety in their 
children, 18% reported increased behaviour problems, and 16% reported sleep-related 
problems. 
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DISCUSSION 
In a well-defined rural population that had been exposed to volcanic ash particles with a 
substantial inhalable fraction for several weeks during the Eyjafjallajökull eruption, we 
found only a small degree of physical health impairments soon after the eruption. No 
hospital admissions, fatalities or life-threatening or serious symptoms or diseases which 
could be attributed to the eruption were found in this study of a cohort. From answers to 
the questionnaires, we could conclude that, compared to the general population sample 
from the BOLD study, the subjects of this study reported a similar prevalence of 
respiratory symptoms and obstructive lung disease. Some symptoms of mental distress 
were found in this study. 
In our study, we contacted the whole population living closest to the volcano and had a 
high participation rate (93%). According to the recruiters, some non-participators 
reported not having any health problems, so the symptom rates presented here may be 
overestimated. On the other hand, some vulnerable individuals may have chosen not to 
participate, or had left the most affected area, which may cause us to underestimate the 
symptom rates.  
To facilitate comparisons with other studies, we used standardised methods both in the 
medical examinations and questionnaires, as well as the spirometry in this survey. 
However, the population is small (N=207, of which 167 were adults) and due to stressful 
circumstances during the test period, not all participants completed the questionnaire, 
which limited the statistical power of our analyses. 
   The tested subjects from the Eyjafjallajökull area had better lung function than the 
general population sample, most likely due to a much lower prevalence of smoking. They 
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also had less obstructed airways when tested again after use of a bronchodilator, probably 
because those with asthma had already increased their bronchodilator treatment during 
the ash fall. Also, the general population sample lived in urban and suburban areas, 
whereas the Eyjafjallajökull area residents were predominantly rural. Previous studies 
have not found changes in lung function in children after volcanic ash exposure, but 
asthma hospitalisation rates have been seen to increase after several eruptions10 11 and a 
dose-response has also been found in a Japanese study of adults with asthma who were 
exposed to volcanic ash.26 
Intermittent symptoms in the eyes and upper respiratory organs were very common, 
but they could be prevented by wearing eye protection and face masks or avoiding 
exposure by staying inside. Icelandic houses are generally quite well insulated with 
windows that shut tightly and seemed to offer some protection.  
It was recorded in several of the medical examination reports that people found the ash 
more irritating in the beginning of the eruption, perhaps because fresh ash particles can 
have chemical compounds on the surface which are later washed away.2 
In a study of the ash from Eyjafjallajökull, Horwell et al. found most samples to have 
little potential for damaging health. The ash contained a negligible amount of crystalline 
silica and though one sample showed some cytotoxicity in in vitro studies, the report 
concluded that the ash was unlikely to have an effect at the levels to which people were 
actually exposed.2 
The first results from a study of lung tissue samples and samples from the 
gastrointestinal tract of animals brought to slaughter from the affected area in the autumn 
of 2010 did not reveal any significant pathology.27 
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During the first days of the eruption, cautions for individuals with respiratory disease 
were issued throughout much of Europe, both by national health authorities but also by 
WHO.28 Symptom surveillance studies, however, have shown a slight increase in the 
number of individuals on the European continent seeking medical help for certain 
symptoms in the period when the region was affected by ash.29 30 
   In our study 39% reported some symptoms of mental distress, as measured by the 
GHQ. This was more then twice as many as in a 2004 study of Icelandic farmers (also 
using the GHQ) where 17% scored above the reference value for mental distress.31 
However, a Japanese study of evacuees following a volcanic eruption reported that 66% 
of participants suffered from mental distress, as measured by the GHQ.14 
   The proportion of participants who showed signs of post-traumatic stress (7%) was 
similar to that found following a large earthquake in the south of Iceland in 2008.32 When 
the eruption was still active, there were substantial disturbances in people's daily routine. 
Some of the fatigue and stress indicated by the high prevalence of mental distress may be 
attributed to the increased workload during the eruption and at the same time the 
uncertainty about one’s own health, the health of others, the livestock and the future. In 
addition, our results showed that increased mental distress might partly be explained by 
the extent of experience of volcanic phenomena, as it was associated with having 
experienced earthquakes related to the eruption, or experiencing threat to one’s own life 
or that of others. On the other hand, those who are distressed may experience these 
phenomena more strongly during an eruption. Information about the possible health 
effects of the ash was needed for the affected individuals. Therefore, early in the eruption, 
collaboration was established with national as well as international experts from WHO 
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and EU, pamphlets were distributed widely. Trauma response teams on behalf of the Red 
Cross were present in the evacuation centres, and a number of community meetings were 
held to inform the affected population.  
 
Conclusion 
During the time when volcanic ash was falling from the Eyjafjallajökull eruption, the 
majority of participants experienced symptoms from eyes and upper airways. Those with 
underlying obstructive lung disease were particularly vulnerable; half of the asthmatic 
adults and all the asthmatic children had more pronounced symptoms during the eruption.  
   Our results indicate that public health measures were effective in relieving symptoms. 
Recommendation to avoid exposure by either staying inside or wearing dust protection 
masks and glasses when outdoors during the ash fall or storms may have contributed to 
mitigation of irritation and symptoms. 
   During a volcanic ash fall intensive medical attention should be aimed at vulnerable 
individuals with underlying respiratory diseases and known mental disorders.  
   Little is known about long-term health effects of exposure to volcanic ash, but 
continuous surveillance and research is necessary as the ash is likely to remain in the 
environment for some years to come. A follow-up study would be helpful in interpreting 
the spirometry results, but no severe health outcomes could be associated with the 
eruption in this study. 
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Table 1 Demographic characteristics and questionnaire-reported symptoms in 
adults living close to the Eyjafjallajökull volcano (n=167) 
 All Males Females 
N  83 (50%) 84 (50%) 
Mean age +/-SD (years) 52 +/- 17 54 +/-18 50 +/-17 
BMI +/-SD (kg/m2) 30.0 +/-7 29.1 +/-5 30.8 +/-8 
Smoking    
    Never 103 (62%) 53 (64%) 50 (60%) 
    Former 34 (20%) 18 (22%) 16 (19%) 
    Current 24 (14%) 11 (13%) 13 (14%) 
Self-reported asthma or COPD a 28 (17%) 10 (12%) 18 (21%) 
Respiratory symptoms 
    Throat and upper airway 
irritation or dryness 
83 (50%) 35 (42%) 48 (57%) 
    Cough 58 (35%) 28 (34%) 30 (35%) 
    Shortness of breath or 
tightness of chest 
43 (26%) 20 (24%) 23 (27%) 
Other symptoms    
    Eye irritation  41 (25%) 17 (20%) 24 (29%) 
    Headaches 15 (9%) 8 (10%) 7 (8%) 
    Nausea and stomach aches 12 (7%) 7 (8%) 5 (6%) 
a As reported in questionnaires (“Have you ever been diagnosed with asthma or COPD”) 
 
Page 23 of 35
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
23 
Table 2 Spirometry results, smoking status, reported chronic respiratory diseases 
and symptoms among participants aged> 40 years compared to age and gender 
matched controls from the general population  
 
 
Participants (n=128) 
mean +/-SD 
Controls (n=384) 
mean +/-SD 
 
 p (t.test) 
Spirometry mean (+/-SD)   
FEV1 % predicteda 94 +/-15 90 +/-17 0,003 
FVC % predicted 98 +/- 15 95 +/- 14 0,105 
FEV1/FVC % predicted  96 +/- 9 93 +/- 11 0,004 
∆FEV1 (% increase after 
bronchodilation) 
3 +/- 7 4 +/-7 <0,000 
COPD n (%) n (%) p (χ2 test) 
GOLD stage I or higherb 25 (20%) 77 (20%) 1 
GOLD stage II or higher 15 (12%) 42 (11%) 0,87 
Self-reported n (%) n(%) p (χ2 test) 
Smoking:  
     Current 
 
19 (15%) 
 
154 (40%) 
 
 
0,00* 
 
     Former 31 (24%) 159 (41%) 
     Never 76 (59%) 71 (18%) 
Ever asthma  21 (20%) 74 (19%) 0,30 
Ever COPD 3 (2%) 6 (2%) 0,70 
Chronic phlegmc 11 (8%) 38 (10%) 0,61 
Chronic coughc 11 (8%) 43 (11%) 0,33 
a
 predicted values from the NHANES cohort.  
b
 Goldstage I COPD, FEV1/FEV1 < 0,7, GOLDSTAGE II COPD, FEV1/FEV1 < 0,7, and 
FEV1 < 80% predicted. 
c
 History of cough or phlegm 3 months or more every year. 
Abbreviations: BOLD, Burden of Obstructive Lung Disease-study; FEV1, Forced 
expiratory volume in 1 second; FVC, Forced vital capacity. 
∆FEV1 : Increase in FEV1 % predicted after use of bronchodilation 
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Table 3 Mental symptoms following the eruption of Eyjafjallajökull  
 Symptoms of 
PTSDa 
General 
Healthb Depression
c Anxietyc Stressc 
Number of valid replies 138 151 132 130 133 
   Casesd 10 (7%) 59 (39%) 9 (7%) 11 (8%) 9 (7%) 
   Females  8/62 (13%) 38/78 (49%) 6/71 (8%) 8/69 (12%) 7/71 (10%) 
   Males 2/76 (3%) 21/71 (30%) 3/62 (5%) 3/61 (5%) 2(62 (3%) 
Age categories      
     18-34 0/27 (0%) 9/32 (29%) 0/27 (0%) 1/27 (4%) 0/26 (0%) 
     35-49 3/36 (8%) 24/39 (62%) 5/35 (14%) 5/33 (15%) 6/34 (17%) 
     50-64 6/41 (15%) 18/47 (38%) 3/39 (8%) 3/40 (8%) 2/40 (5%) 
     >64 1/34 (3%) 8/33 (24%) 1/31 (3%) 2/30 (7%) 1/33 (3%) 
Lived in the evacuated areae      
     Yes     4/59 (7%) 26/69 (38%) 6/58 (10%) 7/57 (12%) 5/59 (8%) 
     No 6/79 (8%) 33/82 (40%) 3/75 (4%) 4/73 (5%) 4/73 (5%) 
a 
 Derived from the Post-traumatic Stress Disorder (PTSD) Symptom Scale -Self Report (PSS-SR) 
b
 Derived from the General Health Questionnaire (GHQ-12) 
c  Derived from the Depression Anxiety Stress Scale (DASS) 
d
 those who scored above the cut-off for the various scales. 
e
 Some areas were evacuated during the early phases of the eruption due to flood risks. 
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Table 4 Mental symptoms and experiences during the eruption of Eyjafjallajökull 
 Symptoms of 
PTSDa 
n=138 
General 
Healthb 
n=151 
Depression
c 
n=132 
Anxietyc 
n=130 
Stressc 
n=133 
Exposure at residence (“From your residence, did you experience any of the following?”)b 
Was awakened by noise (n=157)      
    Yes 5/66 (8%) 38/75 (51%)* 3/63 (5%) 6/64 (9%) 3/63 (5%) 
    No 5/63 (8%) 16/66 (24%) 5/61 (8%) 4/58 (7%) 5/60 (8%) 
Felt earthquakes (n=155)      
    Yes 5/42 (12%) 27/51 (53%) 2/39 (5%)* 3/38 (8%) 2/39 (5%)* 
    No 4/85 (5%) 27/89 (30%) 5/84 (6%) 7/83 (8%) 5/84 (6%) 
Traumatic experiences (“Did you during the eruption... “) 
Think your life was in danger (n=144)     
    Yes 1/6 (17%)* 2/4 (50%) 1/5 (20%)* 0/5 (0%) 1/4 (25%) 
    No 8/126 (6%) 42/123 (34%) 8/123 (7%) 11/120 (9%) 7/123 (6%) 
Think that someone else's life was in danger (n=139) 
       
   
    Yes 4/19 (21%)* 9/16 (56%) 3/18 (17%) 3/17 (29%) 3/17 (18%)* 
    No 5/108 (5%) 33/107 (31%) 5/105 (5%) 6/103 (6%) 4/105 (4%) 
Feel helpless (n=143)      
    Yes 9/30 (30%)* 20/27 (74%)* 8/30 (27%)* 8/29 (28%)* 7/28 (25%)* 
    No 0/101 (0%) 24/100 (24%) 1/98 (1%) 3/96 (3%) 1/99 (1%) 
Feel afraid (n=142)      
    Yes 4/17 (24%)* 10/17 (59%)* 5/18 (28%)* 4/16 (25%)* 3/17 (18%) 
    No 5/113 (4%) 34/108 (31%) 4/108 (4%) 6/107 (6%) 5/108 (5%) 
a 
 
 Derived from the Post-traumatic Stress Disorder (PTSD) Symptom Scale-Self Report (PSS-SR) 
b
 Derived from the General Health Questionnaire (GHQ-12) 
c  Derived from the Depression Anxiety Stress Scale (DASS) 
d
 those who scored above the cut-off for the various scales. 
*Significant difference in exposure rates between cases and non-cases (p < 0.05 in a χ2-test). 
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Legends for the Figures  
  
Figure 1. Map of the study area, which reached from just west of Eyjafjallajökull to Vik 
in the east. The shading illustrates duration and intensity of the ash plume estimated from 
satellite images.  
 
Figure 2. Age distribution of the study participants (n=207) from the Eyjafjallajökull area 
investigated 31 May to 11 June 2010.  
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Map of the study area, which reached from just west of Eyjafjallajökull to Vik in the east. The shading 
illustrates duration and intensity of the ash plume estimated from satellite images.  
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Age distribution of the study participants (n=207) from the Eyjafjallajökull area investigated 31 May to 11 
June 2010.  
256x156mm (120 x 120 DPI)  
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2 
ABSTRACT 
Objectives: Estimate physical and mental health effects of the Eyjafjallajökull volcanic 
eruption on nearby residents. 
Design: Cross sectional study. 
Setting: The Icelandic volcano Eyjafjallajökull erupted 14 April 2010. The eruption 
lasted for about six weeks and was explosive, ejecting some 8 million tons of fine 
particles into the atmosphere. Due to prevailing winds, the ash spread mostly to the south 
and south-east, first over the rural region to the south, later over the Atlantic Ocean and 
Europe, closing European air space for several days.  
Participants: Residents (n=207) of the most ash-exposed rural area south and east of 
the volcano.  
Methods: The study period was 31 May to 11 June 2010. Participants were examined by 
a physician. To ascertain respiratory health, standardised spirometry was performed 
before and after the use of a bronchodilator. All adult participants answered 
questionnaires about mental and physical health, their children’s health and the use of 
protective equipment.  
Results: Every other adult participant reported irritation in eyes and upper airway when 
exposed to volcanic ash. Adults (n=26) and children (n=5) with pre-existing asthma 
frequently reported worsening of their symptoms. No serious health problems  requiring 
hospitalisation could be attributed to the eruption. The majority of the participants 
reported no abnormal physical or mental symptoms to the examining physician. 
Compared to an age- and gender- matched reference group, the ash-exposed participants 
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3 
reported lower smoking rates and were less likely to have ventilation impairment. Less 
than 10% of the participants reported symptoms of stress, anxiety or depression.  
 
Conclusions: Short-term ash exposure was associated with upper airway irritation 
symptoms and exacerbation of pre-existing asthma but did not contribute to serious 
health problems. The exposure did not impair respiratory function compared to controls. 
Outdoor use of protective glasses and face masks was considered protective against 
irritation in eyes and upper airway.  
 
ARTICLE SUMMARY 
Article focus 
• Exposure to volcanic ash and gases can have adverse effects on respiratory health. 
• Natural hazards, such as volcanic eruptions, can be stressful events. 
• Value of preventive measures for those exposed to a volcanic eruption.  
Key messages 
• The short term effects of ash exposure were associated with irritation in eyes and 
upper airway and exacerbation of pre-existing asthma, but did not contribute to 
serious health problems or impair respiratory function as compared to controls. . 
• Participants with pre-existing respiratory and mental conditions need special 
attention and are more prone to developing symptoms following exposure to 
volcanic eruptions and volcanic ash.  
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4 
• The use protective glasses and face masks prevented or relieved irritation 
symptoms from the eyes and upper airway. 
Strengths and limitations of this study 
• The whole population living within a confined area close to the volcano was 
contacted and the response rate was high (93%)  minimising the risk of selection 
bias, though some sensitive individuals had probably left the area, and some 
elderly individuals did not participate in the survey.  
• Standardised methods were used in measuring respiratory function and 
questionnaires were also standardised, allowing for comparisons with other 
studies. 
• Results from the spirometry were compared to results from an age-and gender 
matched Icelandic control group from a previous study which had been performed 
using identical methods. 
• The population was small (N=207) and due to stressful circumstances during the 
test period, not all participants completed the questionnaire, which limited the 
statistical power of our analyses. 
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5 
INTRODUCTION 
On 14 April 2010 an explosive summit crater eruption began in Eyjafjallajökull 
(Eyjafjalla Glacier), a volcano that is situated in south Iceland (figure 1). In the early 
phases of the eruption, fine-grained ash was ejected up to 10 km into the atmosphere, 
disturbing air traffic in Europe for days. In Iceland, the rural regions south and south-east 
of the volcano were heavily exposed to falling ash. The volcano ejected some 250 million 
tons of ash, of which 8 million tons were particles 2.8 - 28 µm in diameter.1-6 Particles 
with a diameter of less than 10 µm are inhalable and can compromise respiratory health. 
Despite the falling ash that changed day to night, many inhabitants, mostly farmers, 
remained in the area to work on their farms and tend their livestock.  
   Apart from the immediate, life-threatening hazards following a volcano eruption, such 
as pyroclastic flows, mudslides and glacial outburst floods, several other health risks are 
associated with living close to an active volcano.7 Short term exposure to volcanic gases 
can trigger asthma attacks, and has been associated with respiratory morbidity and 
mortality and increased irritation of the respiratory tract.8  Exposure for longer time 
periods to volcanic ash and gases have been associated with increases in cardiovascular  
symptoms9 and increased rates of chronic bronchitis and other respiratory symptoms,10 11 
also in children.12 Symptoms of skin and eye irritation have also been reported.13  The 
chemical and physical properties of volcanic ash vary a great deal between eruptions and 
volcanoes, making it difficult to generalise about the toxicity of ash from individual 
eruptions.13 
   Volcanic eruptions are violent natural disasters that impose a threat to health as well as 
to livestock and property. During eruptions the population may have to be evacuated, 
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6 
depending on risk assessment, and uncertainty and stress experienced during the eruption 
can influence mental well-being.14 15   The aim of this study was to examine medically the 
most exposed population and evaluate possible acute physical and mental health effects 
associated with the Eyjafjallajökull eruption. In addition the effectiveness of protective 
measures taken against inhaling ash and eye exposure was evaluated by asking the 
participants for their subjective experience of the measures. 
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7 
METHODS 
The study area of the volcanic eruption 
The volcanic eruption of the Eyjafjallajökull volcanic system began on 20 March 2010 
with a small flank eruption which produced negligible ash. After a day of no volcanic 
activity, an eruption started within the Eyjafjallajökull caldera on 14 April.16 This phase 
was explosive, sending fine-grained, phreato-magmatic ash into the atmosphere. The 
eruption lasted some 6 weeks, until the end of May 2010. Ash exposure around the 
volcano was estimated  using information about the eruption plume from satellite images 
(coarse time resolution), information about the emission intensity1, and information from 
observations on the ground17. Model calculations using FLEXPART6 gave similar 
distribution for the deposited ash, with maximum deposition around 1000 g/m2 (near the 
vent of the volcano), and about 200 g/m2 near Vík During that time the wind direction 
was predominantly west and north-west, therefore most of the ash fall was to the south 
and south-east of the volcano (figure 1). In this study, we included inhabitants of the area 
between the river Markarfljót and the village of Vík as they were most exposed. Most 
inhabitants are farmers and many also have income from tourism. 
 
The volcanic ash 
The ash was trachy-andesitic, 58% silica by mass, but contained very little quartz and no 
cristobalite was detected.1 – 6  In ash samples collected during the first 3 days of the 
eruption, upwards of 25% of particles by mass were less than 10 µm in diameter (PM10) 
and therefore inhalable. The fraction of fine particles was lower for ash ejected later in 
the eruption1 but still the amount of ash produced was considerable, and the fine- grained 
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8 
ash was also easily re-suspended. The concentration of airborne particle matter was very 
high during the eruption.4 
A network of diffusion tubes in the ground area showed no evidence of fumigation by 
sulphur dioxide, the predominant volcanic gas in the ash plume, in the last 3 weeks of the 
eruption (Personal communication: Peter Baxter, 2010). 
 
Target population and recruitment 
During the eruption some 223 individuals lived in the study area and were exposed to ash 
fall. All the inhabitants were invited to a medical examination during the time period 31 
May to 11 June 2010. An announcement was put up in local official buildings and 
information given on radio and TV news. Also, inhabitants were contacted by telephone 
by staff from the two local primary healthcare centres in the area. The majority of 
participants were examined at temporary medical offices at a community centre or at a 
primary health care centre, a few were examined in their homes. 
 
Medical and psychological examination  
A physician interviewed and examined all participants. The doctors in charge were 
specialists in family medicine and respiratory medicine. Former and present physical and 
psychological health was explored. Participants were asked if they experienced any 
change in health or new symptoms that they related to the ash and the volcanic eruption. 
The medical history of young children was obtained from their parents. In case of 
abnormal findings the participants were referred to their Primary Health Care Centre for 
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9 
further examination and treatment.  
 
Spirometry 
The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) 
values were obtained by spirometry in all participants five years or older, according to 
ATS criteria in the same way and by the same field workers as had conducted the Burden 
of Obstructive Lung Disease (BOLD) multicentre study in Iceland.18 19 The spirometry 
was conducted by trained and certified personnel and the medical examination was 
conducted by doctors, all from the Landspitali University Hospital.  
Briefly, testing was conducted with the participant in a sitting position wearing a nose 
clip and a disposable mouthpiece using the NDD Easy One™ spirometer (NDD 
Medizintechnik, Zurich, Switzerland). Pre- and post-bronchodilator tests were carried 
out, with separate measurements performed before and ≥15 minutes after two puffs of 
salbutamol (200 µg). The primary reference equations used are derived from the third 
United States National Health and Nutrition Examination Survey (NHANES III) for adult 
Caucasians.20 
   The criteria for chronic obstructive pulmonary disease (COPD) are defined by the 
Global Initiative of Chronic Obstructive Lung Disease.18 COPD Gold stage 1 was defined 
as FEV1/FVC ratio < 0.7 after bronchodilation and GOLD stage II as FEV1/FVC ratio < 
0.7 and FEV1 ≤ 80% predicted after bronchodilation. Reversibility of airway obstruction 
was calculated as a change in FEV1 and expressed as a change in percentage (∆%). 
   For analysis of the spirometry results in those over 40 years of age, a subset of the 
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10 
BOLD cohort19 was used as a control group, with three age- and gender- matched 
controls from the BOLD (random general) population for each participant exposed to 
volcanic ash.  
 
Questionnaires 
Participants over the age of 18 were asked to fill out questionnaires with questions about 
physical health, mental health, exposure to volcanic ash, experience of earthquakes, 
rumbling and smell from the volcano, and use of protective face masks and glasses. If 
necessary, the questionnaires were read to them by researchers. 
   Respiratory health before the eruption was assessed by the European Community 
Respiratory Health Survey (ECRHS) II questionnaire.21 From the main ECRSH 
Questionnaire, we used questions about wheeze, cough and phlegm prevalence, history of 
respiratory and heart disease (questions number 1-3, 6-10 and 14, and question 7 from the 
screening questionnaire).  
   The participants were also asked if they had experienced other respiratory or eye 
symptoms, muscular pain, fatigue, nausea, headache, stomach pain or insomnia before 
and/or after the eruption started. If the symptoms had started after the eruption they were 
asked to quantify how much these symptoms affected their daily life, on a three point 
scale (rather little, rather much, and very much).  
   Parents answered seven questions about respiratory symptoms, headache, stomach 
ache, insomnia, anxiety, depression and behavioural changes in children under 18 years 
of age. If these symptoms had started after the eruption they were asked to quantify them 
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11 
on a three-level scale.  
   There were also questions about medical emergencies and use of medication, injuries 
and accidents related to the eruption.  
   Mental health was assessed with three different psychometric scales which all had 
previously been translated into Icelandic and used in other studies. When measuring 
psychological morbidity in relationship with the eruption, we used the General Health 
Questionnaire (GHQ-12),22 23 the Depression, Anxiety and Stress Scale (DASS)24 and 
the Post-Traumatic Stress Disorder (PTSD) Symptom Scale, Self-Report version (PSS-
SR).25 26 Each questionnaire was evaluated, and, if inadequately answered, excluded. 
   For GHQ-12, a score of more than 2 was considered indicative of experiencing more 
mental distress than usual (Bimodal score).22 
   For PSS-SR, a score of more than 14 considered indicative of likelihood of PTSD-
symptoms in the participants.25 26 
   For DASS, a score was given for each of the three dimensions addressed in the 
questionnaire. A score of more than 10 for depression, 8 for anxiety, and 15 for stress 
indicate symptom severity, from mild to extreme, as defined by Lovibond and 
Lovibond.24 DASS and PSS-SR questionnaires were not administered on the first day of 
the study, but participants were given the option of filling out the questionnaires and 
mailing them.  
   Participants were asked how they had experienced ash fall, heard or been awakened by 
noise from the volcano, felt earthquakes, smell, or limited vision outside due to ash fall at 
their homes, how many days they to stay inside because of ash fall, how many hours they 
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12 
usually worked outdoors and if they had used protective equipment. Finally, participants 
were asked if they had received help or services from a number of organisations and 
institutions, and if they were satisfied with it. 
   Smoking history was investigated by asking participants whether they were current 
smokers, ex-smokers or never-smokers. Based on this information the participants were 
classified into Never-smoker, Ex-smoker, and Smoker. 
 
Statistical analysis 
All data were entered into a database by one observer. The analysis was mainly 
descriptive, and the primary outcome measure was prevalence in percentage (%) of the 
total number of answers in the given category. In comparisons between groups, we used 
student's t-test and χ2 test. Individuals with incomplete data were not excluded from the 
study, but non-replies to any single questions were excluded from individual analyses. We 
used SPSS software version 18 and R.27  
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13 
RESULTS 
Altogether 207 out of 223 individuals (93%) who lived in the study area at the time of the 
eruption participated in the study. Local health workers, who recruited the participants, 
reported that inhabitants of two of about 80 farms had refused to participate, and 14 
individuals who had initially signed up did not participate. 
   The most common reason for non-participation reported to the recruiters was either 
“being busy”, “not having any health problems” , or “old age” (reported by relatives). Of 
the 207 participating residents, 40 were under 18 years of age. Most of them, 202 (98%) 
were medically examined, 164 adults and 38 children. The same proportion was tested 
with spirometry, and 156 adults were tested both before and after bronchodilation. All 
adults received questionnaires about symptoms and general health (GHQ-12). PSS-SR 
and DASS were administered to 150 people. Main demographic characteristics, 
symptom- and smoking rates reported in adults are shown in table 1. The survey included 
40 children under 18 years of age of which 21 (53%) were girls.  
    The age distribution of all participants is given in figure 2. 
 
Physical examination 
The physician’s judgement was that 126 (62%) of the participants were healthy. In the 
physician interview, 26 (13%) of adults reported history of asthma or other chronic 
respiratory diseases, 32 (16%) reported symptoms and signs other than respiratory, and 
27 (13%) participants indicated a history of mental symptoms. Asthma rates reported to 
physicians were similar to that reported in questionnaires. Of those with a history of 
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14 
asthma or other respiratory diseases, 38% had a normal spirometric test but 39% reported 
worsening of the disease when exposed to ash. The rates of chronic cough and phlegm 
was similar in the study participants and the reference group (8-10%). Smoking was more 
common in the reference group than the volcano-exposed participants (p<0.01) (table 1). 
Some reported to physicians that upper respiratory symptoms subsided when avoiding 
exposure by staying inside or wearing dust masks and also that falling “fresh” ash was 
more bothersome than “older” ash re-suspended by wind. Farming was reported as the 
main occupation (63%) of adult participants.  
 
Spirometry  
Among the 202 participants who underwent spirometry 37 (18%) were found to have 
impaired respiratory function by the examining physician.  
Participants aged 40 years or older had on average a higher FEV1 than the reference 
group (p=0.003) and they also showed less airflow reversibility (p<0.0001). After 
bronchodilation, 20% of those 40 years of age or older fulfilled the criteria for COPD 
stage I or higher, which was identical to that found among the general population 
reference group (table 2). 
The 35 children who were tested with spirometry had in average normal percent of 
predicted FEV1 (102% +/-19%; mean, one SD) and FVC (104% +/- 17%). Altogether 
four had FEV1 % predicted lower than 85%; Two of these had  preexisting asthma and 
revieled symptoms when examined (FEV1 48% and 76% respectively), but the other two 
were previously healthy but both had symptoms of upper airway virus infection (FEV1 
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15 
71% and 81%) when examined. 
 
Questionnaires 
Almost half of the adult participants (43%) experienced symptoms from the upper 
airways and eyes during the ash fall. Almost everybody or 153 of 161 (96%) found facial 
mask and glasses protective against respiratory and eye symptoms when staying outdoor 
during ash fall. All participants of the study were exposed to ash fall at their homes and 
almost all (88%) had to stay inside at least one day and one third (34%) for 6 days or 
more, which may explain some of the mental distress and child behavioural problems. 
Also, avoiding exposure by staying in the well-isolated houses may have kept symptom 
rates down. Almost everyone (98%) had heard the explosions from the mountain at their 
home and 53% had woken up at night because of noise but there was no obvious 
geographical pattern to this. The most common self-reported symptoms reported by adult 
participants are shown in table 1. Men and women had similar rates of symptoms, except 
that women tended to report more throat and upper airway irritation (p=0.06, Student’s t-
test). 
   Females reported more frequently mental health deterioration than men, according to 
the General Health Questionnaire (GHQ) and Depression, Anxiety, Stress Scale (DASS) 
and the highest rates were found in those between 35-49 years of age (table 3). Symptoms 
of post-traumatic stress syndrome (PSS-SR) were found in 7% of participants, and were 
more common among females than males and in those slightly older (50-64 years old). 
Very little effect on mental health was reported in the age-group 18-34 years of age. 
Page 15 of 38
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 
16 
   Table 4 shows the proportions of participants experiencing mental distress by level of 
exposure (experience of the volcanic eruption). Experiencing a feeling of helplessness or 
fear for the lives of others or oneself during the eruption period was associated with 
higher rates of likely PTSD symptoms. The frequency of mental distress (as measured by 
GHQ) was significantly (p<0.05) higher in those who had been awakened by noise. 
   Symptoms of depression and anxiety (DASS) were more common among those who 
had experienced earthquakes and had thought that their lives were in danger (table 4). 
   Many children of school age were not in the area during the heaviest ash fall. A 
boarding school outside the affected region invited the Eyjafjallajökull children to stay 
for some weeks. By the time the health survey was carried out, most were in the area. 
Nevertheless, 13 (28%) of parents reported in the questionnaires that their child had 
experienced throat or upper airway irritation symptoms (data not shown). Eight (13%) 
reported headaches, while three parents (7%) reported that their child or children had had 
nausea or stomach pain during the eruption. Of the 40 participating children, 5 had a 
previous history of asthma and they all reported in the medical interview that they had 
had more symptoms during the ash fall and needed more anti-asthmatic medication than 
usual. Regarding mental distress, 39% of participants with children reported increased 
worries or anxiety in their children, 18% reported increased behaviour problems, and 
16% reported sleep-related problems. 
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17 
DISCUSSION 
In a well-defined rural population that had been exposed to volcanic ash particles with a 
substantial inhalable fraction for several weeks during the Eyjafjallajökull eruption, we 
found only a small degree of physical health impairments soon after the eruption. No 
hospital admissions, fatalities or life-threatening or serious symptoms or diseases which 
could be attributed to the eruption were found in this study of a cohort. From answers to 
the questionnaires, we could conclude that, compared to the general population sample 
from the BOLD study, the study participants reported a similar prevalence of respiratory 
symptoms and obstructive lung disease. Some symptoms of mental distress were found in 
this study. 
In our study, we contacted the whole population living closest to the volcano and had a 
high participation rate (93%). According to the recruiters, some non-participators 
reported not having any health problems, so the symptom rates presented here may be 
overestimated. There may also be a recall bias, so that those who are worried about their 
health are more likely to participate and recall symptoms. On the other hand, some 
vulnerable individuals may have chosen not to participate, or had left the most affected 
area, which may cause us to underestimate the symptom rates. 
To facilitate comparisons with other studies, we used standardised methods both in the 
medical examinations and questionnaires, as well as the spirometry in this survey. 
However, the population is small (N=207, of which 167 were adults) and due to stressful 
circumstances during the test period, not all participants completed the questionnaire, 
which limited the statistical power of our analyses. 
   The participants from the Eyjafjallajökull area had better lung function than the general 
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18 
population sample, most likely due to a much lower prevalence of smoking. They also 
had less obstructed airways when tested again after use of a bronchodilator, probably 
because those with asthma had already increased their bronchodilator treatment during 
the ash fall. Also, the general population reference sample lived in urban and suburban 
areas, whereas the Eyjafjallajökull area is predominantly rural. The children had normal 
spirometry measurements. Previous studies have not found changes in lung function in 
children after volcanic ash exposure, but asthma hospitalisation rates have been seen to 
increase after several eruptions12 13  and a dose-response has also been found in a 
Japanese study of asthmatic adults who were exposed to volcanic ash.28 
Intermittent symptoms in the eyes and upper respiratory organs were very common, but 
they could be prevented by wearing eye protection and face masks or avoiding exposure 
by staying inside. Facial masks and glasses for eye protection were made widely and 
freely available by the public health authorities. These protective equipment were in 
plentiful supplies purchased for the swine flu epidemic the previous year. Icelandic 
houses are generally quite well insulated with windows that shut tightly and seemed to 
offer some protection.  
It was recorded in several of the medical examination reports that people found the ash 
more irritating in the beginning of the eruption, perhaps because fresh ash particles can 
have chemical compounds on the surface which are later washed away.2 
In a study of the ash from Eyjafjallajökull, Horwell et al. found most samples to have 
little potential for damaging health. The ash contained a negligible amount of crystalline 
silica and though one sample showed some cytotoxicity in in vitro studies, the report 
concluded that the ash was unlikely to have an effect at the levels to which people were 
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19 
actually exposed.2 
The first results from a study of lung tissue samples and samples from the 
gastrointestinal tract of animals brought to slaughter from the affected area in the autumn 
of 2010 did not reveal any significant pathology.29 
During the first days of the eruption, precautions for individuals with respiratory 
disease were issued throughout much of Europe, both by national health authorities but 
also by WHO.30 Symptom surveillance studies, however, have shown a slight increase in 
the number of individuals on the European continent seeking medical help for certain 
symptoms in the period when the region was affected by ash.31 32 
   In our study 39% of participants reported some symptoms of mental distress, as 
measured by the GHQ. A high GHQ score was associated with feeling helpless or afraid, 
or being awakened by noises from the volcano. The rate of GHQ cases in this study was 
more than twice as many as in a 2004 study of Icelandic farmers where 17% scored 
above the reference value for mental distress in GHQ.33 However, in a Japanese study of 
a population exposed to a volcanic eruption, 66% were found to suffer from mental 
distress, but this population had been evacuated and were unable to return to their home 
region for years.[15] Only half of the participants in this study population were 
evacuated, and then only for a few days.  
   The proportion of participants who exhibited symptoms of post-traumatic stress (7%) 
was similar to that found following a large earthquake in the south of Iceland in 2008.34 
When the eruption was still active, there were substantial disturbances in people's daily 
routine. Some of the fatigue and stress indicated by the high prevalence of mental distress 
may be attributed to the increased workload during the eruption and at the same time the 
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20 
uncertainty about one’s own health, the health of others, the livestock and the future. In 
addition, our results showed that increased mental distress might partly be explained by 
the extent of experience of volcanic phenomena, as it was associated with having 
experienced earthquakes related to the eruption, or experiencing threat to one’s own life 
or that of others. On the other hand, those who are distressed may experience these 
phenomena more strongly during an eruption. Information about the possible health 
effects of the ash was needed for the affected individuals. Therefore, early in the eruption, 
collaboration was established with national as well as international experts from WHO 
and EU, and the International Volcanic Health Hazards Network, whose pamphlets were 
translated into Icelandic and distributed widely.35 Trauma response teams on behalf of the 
Red Cross were present in the evacuation and community centres, and a number of 
community meetings were held to inform the affected population.  
 
Conclusion 
During the time when volcanic ash was falling from the Eyjafjallajökull eruption, the 
<majority of participants experienced symptoms from eyes and upper airways. Those 
with underlying obstructive lung disease were particularly vulnerable; half of the 
asthmatic adults and all the asthmatic children had more pronounced symptoms during 
the eruption.  
   Our results indicate that public health measures were effective in relieving symptoms. 
Recommendation to avoid exposure by either staying inside or wearing dust protection 
masks and glasses when outdoors during the ash fall or storms may have contributed to 
mitigation of irritation and symptoms. 
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   During a volcanic ash fall intensive medical attention should be aimed at vulnerable 
individuals with underlying respiratory diseases and known mental disorders.  
   Little is known about long-term health effects of exposure to volcanic ash, but 
continuous surveillance and research is necessary as the ash is likely to remain in the 
environment for some years to come. A follow-up study would be helpful in interpreting 
the spirometry results, but no severe health outcomes could be associated with the 
eruption in this study. 
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23 
Table 1 Demographic characteristics and questionnaire-reported symptoms in 
participants who all lived close to the Eyjafjallajökull volcano (n=167) 
 All Males Females 
N  83 (50%) 84 (50%) 
Mean age +/-SD (years) 52 +/- 17 54 +/-18 50 +/-17 
BMI +/-SD (kg/m2) 30.0 +/-7 29.1 +/-5 30.8 +/-8 
Smoking    
    Never 103 (62%) 53 (64%) 50 (60%) 
    Former 34 (20%) 18 (22%) 16 (19%) 
    Current 24 (14%) 11 (13%) 13 (14%) 
Self-reported asthma or COPD a 28 (17%) 10 (12%) 18 (21%) 
Respiratory symptoms 
    Throat and upper airway 
irritation or dryness 
83 (50%) 35 (42%) 48 (57%) 
    Cough 58 (35%) 28 (34%) 30 (35%) 
    Shortness of breath or 
tightness of chest 
43 (26%) 20 (24%) 23 (27%) 
Other symptoms    
    Eye irritation  41 (25%) 17 (20%) 24 (29%) 
    Headaches 15 (9%) 8 (10%) 7 (8%) 
    Nausea and stomach aches 12 (7%) 7 (8%) 5 (6%) 
a As reported in questionnaires (“Have you ever been diagnosed with asthma or COPD”) 
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Table 2 Spirometry results, smoking status, reported chronic respiratory diseases 
and symptoms among participants aged> 40 years compared to an age- and gender 
matched reference group from the general population  
 
 
Participants (n=128) 
mean +/-SD 
Controls (n=384) 
mean +/-SD 
 
 p (t.test) 
Spirometry   
FEV1 % predicteda 94 +/-15 90 +/-17 0,003 
FVC % predicted 98 +/- 15 95 +/- 14 0,105 
FEV1/FVC % predicted  96 +/- 9 93 +/- 11 0,004 
∆FEV1 (% increase after 
bronchodilation) 
3 +/- 7 4 +/-7 <0,000 
COPD n (%) n (%) p (χ2 test) 
GOLD stage I or higherb 25 (20%) 77 (20%) 1 
GOLD stage II or higher 15 (12%) 42 (11%) 0,87 
Self-reported n (%) n(%) p (χ2 test) 
Smoking:  
    Current 
 
19 (15%) 
 
154 (40%) 
 
 
0,00* 
 
    Former 31 (24%) 159 (41%) 
    Never 76 (59%) 71 (18%) 
Ever asthma  21 (20%) 74 (19%) 0,30 
Ever COPD 3 (2%) 6 (2%) 0,70 
Chronic phlegmc 11 (8%) 38 (10%) 0,61 
Chronic coughc 11 (8%) 43 (11%) 0,33 
a
 predicted values from the NHANES cohort.  
b
 Goldstage I COPD, FEV1/FEV1 < 0,7, GOLDSTAGE II COPD, FEV1/FEV1 < 0,7, and 
FEV1 < 80% predicted. 
c
 History of cough or phlegm three months or more every year. 
Abbreviations: BOLD, Burden of Obstructive Lung Disease-study; FEV1, Forced 
expiratory volume in 1 second; FVC, Forced vital capacity. 
∆FEV1 : Increase in FEV1 % predicted after use of bronchodilation 
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Table 3 Mental symptoms following the eruption of Eyjafjallajökull  
 Likelihood of 
PTSDa 
General 
Healthb Depression
c Anxietyc Stressc 
Number of valid replies 138 151 132 130 133 
    Casesd 10 (7%) 59 (39%) 9 (7%) 11 (8%) 9 (7%) 
    Females  8/62 (13%) 38/78 (49%) 6/71 (8%) 8/69 (12%) 7/71 (10%) 
    Males 2/76 (3%) 21/71 (30%) 3/62 (5%) 3/61 (5%) 2(62 (3%) 
Age categories      
    18-34 0/27 (0%) 9/32 (29%) 0/27 (0%) 1/27 (4%) 0/26 (0%) 
    35-49 3/36 (8%) 24/39 (62%) 5/35 (14%) 5/33 (15%) 6/34 (17%) 
    50-64 6/41 (15%) 18/47 (38%) 3/39 (8%) 3/40 (8%) 2/40 (5%) 
    >64 1/34 (3%) 8/33 (24%) 1/31 (3%) 2/30 (7%) 1/33 (3%) 
Lived in the evacuation 
zonee 
     
    Yes  4/59 (7%) 26/69 (38%) 6/58 (10%) 7/57 (12%) 5/59 (8%) 
    No 6/79 (8%) 33/82 (40%) 3/75 (4%) 4/73 (5%) 4/73 (5%) 
a 
 Derived from the Post-traumatic Stress Disorder (PTSD) Symptom Scale -Self Report (PSS-SR) 
b
 Derived from the General Health Questionnaire (GHQ-12) 
c  Derived from the Depression Anxiety Stress Scale (DASS) 
d
 those who scored above the cut-off for the various scales. 
e
 Some areas were evacuated in the first days of the eruption due to flood risks. 
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Table 4 Mental symptoms and experiences during the eruption of Eyjafjallajökull 
 Likelihood of 
PTSDa 
n=138 
General 
Healthb 
n=151 
Depression
c 
n=132 
Anxietyc 
n=130 
Stressc 
n=133 
Exposure at residence (“From your residence, did you experience any of the following?”)b 
Was awakened by noise (n=157)      
    Yes 5/66 (8%) 38/75 (51%)* 3/63 (5%) 6/64 (9%) 3/63 (5%) 
    No 5/63 (8%) 16/66 (24%) 5/61 (8%) 4/58 (7%) 5/60 (8%) 
Felt earthquakes (n=155)      
    Yes 5/42 (12%) 27/51 (53%) 2/39 (5%)* 3/38 (8%) 2/39 (5%)* 
    No 4/85 (5%) 27/89 (30%) 5/84 (6%) 7/83 (8%) 5/84 (6%) 
Traumatic experiences (“Did you during the eruption... “) 
Think your life was in danger (n=144)     
    Yes 1/6 (17%)* 2/4 (50%) 1/5 (20%)* 0/5 (0%) 1/4 (25%) 
    No 8/126 (6%) 42/123 (34%) 8/123 (7%) 11/120 (9%) 7/123 (6%) 
Think that someone else's life was in danger (n=139) 
       
   
    Yes 4/19 (21%)* 9/16 (56%) 3/18 (17%) 3/17 (29%) 3/17 (18%)* 
    No 5/108 (5%) 33/107 (31%) 5/105 (5%) 6/103 (6%) 4/105 (4%) 
Feel helpless (n=143)      
    Yes 9/30 (30%)* 20/27 (74%)* 8/30 (27%)* 8/29 (28%)* 7/28 (25%)* 
    No 0/101 (0%) 24/100 (24%) 1/98 (1%) 3/96 (3%) 1/99 (1%) 
Feel afraid (n=142)      
    Yes 4/17 (24%)* 10/17 (59%)* 5/18 (28%)* 4/16 (25%)* 3/17 (18%) 
    No 5/113 (4%) 34/108 (31%) 4/108 (4%) 6/107 (6%) 5/108 (5%) 
a 
 
 Derived from the Post-traumatic Stress Disorder (PTSD) Symptom Scale-Self Report (PSS-SR) 
b
 Derived from the General Health Questionnaire (GHQ-12) 
c  Derived from the Depression Anxiety Stress Scale (DASS) 
d
 those who scored above the cut-off for the various scales. 
*Significant difference in exposure rates between cases and non-cases (p < 0.05 in a χ2-test). 
 
Page 26 of 38
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
group.bmj.com on June 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
For peer review only
 
27 
Legends for the Figures  
  
Figure 1. Map of the study area, which reached from just west of Eyjafjallajökull to Vik 
in the east. The shading illustrates duration and intensity of the ash plume. The darkest 
areas represent an estimated ash deposition of >500 g/m2, and around Vik the deposition 
is estimated around 200 g/m2. 
 
Figure 2. Age distribution of the study participants (n=207) from the Eyjafjallajökull area 
investigated 31 May to 11 June 2010.  
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STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology* 
Checklist for cohort, case-control, and cross-sectional studies (combined) 
Section/Topic Item # Recommendation Reported on page # 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 2 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 2-3 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 4 
Objectives 3 State specific objectives, including any pre-specified hypotheses 5 
Methods  
Study design 4 Present key elements of study design early in the paper 2-7 (title, abstract, 
introduction, 
methods) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data 
collection 
7 (eruption),  
8 (recruitment) 
9-12 (data collected) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
8 (target population 
and recruitment) 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
- 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable 
9-12 (define 
outcomes) 
10-12 (diagnostic 
criteria – coding of 
variables) 
Data sources/ measurement 8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
10-12 
Bias 9 Describe any efforts to address potential sources of bias Reporting bias  is 
discussed on page 17. 
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Study size 10 Explain how the study size was arrived at 13  
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen 
and why 
10-11-12 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 12 
(b) Describe any methods used to examine subgroups and interactions 12 
(c) Explain how missing data were addressed 12 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
None were done. 
(e) Describe any sensitivity analyses - 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed 
13 
  (b) Give reasons for non-participation at each stage 13 
  (c) Consider use of a flow diagram  - 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders 
22 
  (b) Indicate number of participants with missing data for each variable of interest 23,24,25 
  (c) Cohort study—Summarise follow-up time (eg, average and total amount) - 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time - 
  Case-control study—Report numbers in each exposure category, or summary measures of exposure - 
  Cross-sectional study—Report numbers of outcome events or summary measures 24, 25 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
24,  25, 26 
  (b) Report category boundaries when continuous variables were categorized 25, 25 
  (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period - 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses - (no other was done) 
Discussion  
Key results 18 Summarise key results with reference to study objectives 17 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias 
17 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence 
17-19 
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Generalisability 21 Discuss the generalisability (external validity) of the study results 17-19 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on 
which the present article is based 
21 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
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